LINC01727: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01727

NCBI ID: G101929625

LINC01727

Other Name(s): long intergenic non-protein coding RNA 1727 | IRENA | Long intergenic non-protein coding RNA 1727

LINC01727: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01727 is a long non-coding RNA (lncRNA) that has been identified in various cellular processes and has been associated with various diseases, including cancer. It has been predicted to play a critical role in the regulation of cell adhesion, migration, and invasion, making it an attractive drug target and a potential biomarker for various diseases.

Disease-Related Characteristics

LINC01727 has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. It has been shown to be overexpressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Overexpression of LINC01727 has been associated with increased cell proliferation, migration, and invasion, promoting the development of cancer and neurodegenerative diseases.

In addition, LINC01727 has also been associated with various signaling pathways, including the NF-kappa pathway, which plays a critical role in cell adhesion, migration, and invasion. Activation of the NF-kappa pathway has been shown to promote the overexpression of LINC01727, leading to its association with disease.

Drug Target Potential

LINC01727 has been predicted to have a high potential for drug targeting due to its unique structure and its involvement in various cellular processes. It is a long non-coding RNA, which means it has a length of over 200 nucleotides. This length allows for a wide range of potential drug targets. Additionally, LINC01727 has a highly conserved sequence, which makes it a promising candidate for small molecules that can interact with it.

One potential drug target for LINC01727 is the NF-kappa pathway. Activation of the NF-kappa pathway has been shown to promote the overexpression of LINC01727, making it a potential target for small molecules that can inhibit the pathway. Additionally, LINC01727 has been shown to play a critical role in the regulation of cell adhesion, which is a crucial aspect of the NF-kappa pathway. Therefore, small molecules that can inhibit cell adhesion and disrupt the NF-kappa pathway could be an effective drug targets for LINC01727.

Biomarker Potential

LINC01727 has also been predicted to have a high potential as a biomarker for various diseases. Its association with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases, makes it an attractive candidate for biomarkers. Additionally, LINC01727 has been shown to be overexpressed in various diseases, which could be used as a reliable biomarker for disease progression.

Conclusion

In conclusion, LINC01727 is a long non-coding RNA that has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its high potential as a drug target and biomarker makes it an attractive candidate for further research. The development of small molecules that can inhibit the NF-kappa pathway and disrupt cell adhesion as well as the identification of biomarkers for various diseases associated with LINC01727 could have a significant impact on our understanding of these diseases and their treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 1727

The "LINC01727 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01727 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets